Pharmacogenomics Testing Services
Value
Estimated€981,246 · 822,480 GBP
Awarded€981,246 · 822,480 GBP
WinnerC-Tric Limited
CPV codes
85148000 Health & social work services71900000 Architecture, engineering & inspectionDescription
The project wishes to appoint a suitable lab or labs to provide an end-to-end genomic testing service to provide genomic variant data for n=6,500 participants in a UK and Ireland. The project wishes to appoint a suitable laboratory or multiple labs to supply an end-to-end genomic testing service which provides genomic variant data for n=6,500 participants in UK and Ireland. The iMPROVE project will operate on the basis of a research implementation study which aims to integrate pharmacogenomic testing into a patient-centred medicines optimisation care pathway in GP practices across the project regions. Specifically, the areas of the UK and Ireland where the project will recruit participants from includes: counties Londonderry, Tyrone in Northern Ireland, counties Donegal and Sligo.
Similar tenders
Closest by meaning — across languages, via embeddings.
| Published | Title | Buyer | Match |
|---|---|---|---|
| 2026-05-18 | Pharmogenomics Testing Services | University Of Ulster IE | 99% |
| 2026-09-08 | Laboratory Testing Services for the National Wastewater Surveillance Programme | Health Service Executive (HSE) IE | 87% |
| 2026-10-08 | MLPA-Based CNV Testing for BRCA1/BRCA2 | HUS Group, the joint authority for Helsinki and Uusimaa FI | 86% |
| 2026-10-14 | Pipetting robot for the department for pathology at St. Olavs Hospital. | SYKEHUSINNKJØP HF NO | 86% |
| 2026-09-10 | SPR/260834 - Provision of genomic epidemiology and public health bioinformatics training | European Centre for Disease Prevention and Control SE | 86% |
| 2026-05-28 | Servicii de Secventiere Genomica, necesare pentru efectuarea activitatilor de cercetare in cadrul poiectului de cercetare PNRR-III-C9-2023-I8, Contract de finanţare nr. 760278/26.03.2024, cu titlul "Creating a Research Group of Excellence to develop cell and immune therapy technology to target the tumor microenvironment" | Universitatea de Medicina si Farmacie "Iuliu Hatieganu" Cluj-Napoca RO | 86% |